SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
Rhythm
Murj® Expands Global Footprint with Commercial Launch in Australia and New Zealand
SYDNEY and AUCKLAND, New Zealand, June 21, 2026 /PRNewswire/ — Murj®, a cardiac device management software company, today announced its official expansion into the Australian market alongside broader availability for New Zealand. Following its exhibition at the recent CSANZ / HRS…
AHN’s Allegheny General Hospital Unveils New, State-of-the-Art Cardiac Cath and Electrophysiology Labs, following Completion of $19 Million Renovation Project
New Cardiac Unit Supports Innovative New Procedures, Including Pulsed Field Ablation for Heart Rhythm Disorders PITTSBURGH, June 18, 2026 /PRNewswire/ — Allegheny Health Network’s (AHN) Allegheny General Hospital (AGH) today announced completion of a $19 million renovation and expansion…
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled “Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Fl
Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic’s commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of technologies GALWAY, Ireland, June 3, 2026 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global…
AccurKardia Granted Patent for AI-Driven ECG Detection of Cardiac Amyloidosis
NEW YORK–(BUSINESS WIRE)– #BetterOutcomes–AccurKardia, Inc., an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced that it has been granted US Patent No. 12,620,488 for the company’s proprietary machine-learning-based system for identifying cardiac amyloidosis from a standard, routinely performed 12-lead ECG. Cardiac amyloidosis is a serious, often fatal heart disease in which abnormal proteins build up in heart tissue, causing the heart muscle to stiffen and even
Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia
LAGUNA HILLS, Calif.–(BUSINESS WIRE)—- $ADGM #ARRHYTHMIA–Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the submission of its Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (“VT”) in patients with isch
HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic
RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
World’s Leading Provider of Cutting-Edge Smart Ring Solutions NEW YORK, May 10, 2026 /PRNewswire/ — RingConn opened Gen 3 pre-orders on May 5th ahead of its official May 29th launch, marking the occasion with a feature on the iconic One Times Square billboard in New York City on the…
AccurKardia’s AK+ Guard™ Named “Best New ECG Technology Solution” By MedTech Breakthrough
NEW YORK–(BUSINESS WIRE)– #Cardiology–AccurKardia, an innovator in ECG-based diagnostics technology, today announced that AK+ Guard™ has been selected as winner of the “Best New ECG Technology Solution” award in the 10th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market. AI-powered AK+ Guard hyperkale
Recent
Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
Medera Announces Independent Data Monitoring Committee (DMC) Recommends Continued Advancement of Lead HFpEF Gene Therapy Program
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
Popular
- No commented posts yet